Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
October 02, 2024 09:00 ET
|
Eliem Therapeutics, Inc.
Name change to "Climb Bio" marks the Company’s transition and focus on developing treatments for immune-mediated diseases Climb Bio will begin trading on Nasdaq under the trading symbol "CLYM"...
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
September 11, 2024 07:00 ET
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024...
Eliem Therapeutics Announces Additions to its Leadership Team
August 26, 2024 07:00 ET
|
Eliem Therapeutics, Inc.
Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D. appointed Senior Vice President, Clinical Development SEATTLE and CAMBRIDGE, United Kingdom, Aug. 26, 2024 (GLOBE...
Eliem Therapeutics Reports Second Quarter Financial Results
August 14, 2024 06:05 ET
|
Eliem Therapeutics, Inc.
Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously...
Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes
June 28, 2024 07:00 ET
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the...
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
June 27, 2024 16:01 ET
|
Eliem Therapeutics, Inc.
Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous...
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
April 11, 2024 07:00 ET
|
Eliem Therapeutics, Inc.
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash...
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
July 20, 2023 06:45 ET
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status...
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
May 11, 2023 16:10 ET
|
Eliem Therapeutics, Inc.
Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability ...
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights
March 06, 2023 16:10 ET
|
Eliem Therapeutics, Inc.
Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash...